Network of radiologists across the UK deploying Callisto’s pioneering CaRi-Heart® solution

OXFORD, England, March 19, 2024 /PRNewswire/ — Heart and lung health (HLH), Our UK-wide network of over 110 specialist cardiothoracic radiologists callisto diagnosis, The leading heart disease diagnostics company offers new CaRi-Heart® AI technology that predicts a patient’s risk of developing potentially fatal coronary artery disease.

An estimated 1 million adults in the UK suffer from chest pain each year¹. Many people have a coronary computed tomography angiography (CCTA) scan to diagnose coronary artery disease, which is caused by plaque that narrows or blocks the arteries that supply blood to the heart. However, three-quarters of these patients undergoing CCTA do not show obvious signs of significant stenosis and have traditionally been considered to be at low risk of having a heart attack. However, these “low-risk” patients have twice as many deaths or cardiac events as those identified as high-risk.² The main cause of these events is coronary artery inflammation, an important risk factor not previously seen in routine CCTA.

Coronary artery inflammation is now detectable for the first time on routine CCTA using Callisto. CaRi-Heart technology. Based on research begun at the University of Oxford, CaRi-Heart is a pioneering AI technology that predicts heart attack risk by assessing coronary artery inflammation and integrating clinical risk factors such as plaque and cholesterol levels.This technology provides a non-invasive fat loss index score^™ (FAI score^™) Patented as a biomarker for coronary artery inflammation.

Studies have shown that among patients who had no plaque and zero calcium at the time of CCTA, those who had the most abnormalities CaRi-Heart Test results showed 11 times higher risk of cardiac death and 5 times higher risk of major adverse cardiac events (MACE) compared to normal people CaRi-Heart Test results.

With the new partnership, HLH will offer: CaRi-Heart AI-based cardiac assessments are carried out as a regular part of the organization’s heart health screening package at multiple sites across the UK. HLH provides access to award-winning cardiothoracic radiologists with targeted expertise in diagnosing pulmonary and cardiac conditions. The HLH Network provides specialist reporting services to the UK’s National Health Service (NHS), as well as a wide range of hospitals and academic institutions. HLH has also established itself as a leading provider of lung cancer screening reporting services to the NHS England Targeted Lung Health Check (TLHC) programme.Each patient was screened by CaRi-Heart The HLH radiologist will receive care from the referring clinician. Either your consultant cardiologist or your GP will manage any cardiac risks identified from your diagnostic results. CaRi-Heart technology.

“HLH’s vision is to provide fast, reliable imaging reports focused on delivering world-class patient care. We are pleased to expand access to our award-winning reports.” CaRi-Heart All of our UK sites have AI technology in place. Inflammatory risk pathways could facilitate early diagnosis of patients at risk of heart attack, potentially saving thousands of lives. ” Dr. Jonathan Rodriguez, Chief Medical Officer and Co-Founder of Heart & Lung Health;

In 2022, RadNet, Inc. (www.radnet.com), a publicly traded company based in the United States, acquired a 75% interest in HLH. Radnet is a leading national provider of autonomous fixed-site diagnostic imaging services and related information technology solutions, including artificial intelligence. RadNet has approximately 9,000 total employees.

“Early diagnosis and intervention has the potential to significantly improve health outcomes for thousands of patients at risk for coronary artery disease. We are pleased to announce our partnership with Heart & Lung Health to enhance access to technology in the UK.” Frank Chen, CEO of Callisto Diagnostics, said:

About Callisto diagnosis

Caristo Diagnostics is a global leader in the diagnosis and risk prediction of heart and vascular disease. Founded in 2018 as a spin-out from the world’s number one research university, the University of Oxford, Caristo has developed a portfolio of image-based and AI-assisted platforms that can be applied to help predict and diagnose heart attacks. . such as stroke and diabetes. Callisto was featured in Nature as one of the most exciting science-based companies to emerge from academic research in 2020.

of CaRi-Heart The technology is currently in clinical use in various NHS and private hospitals in the UK, as well as the EU and Australia. It has shown excellent validation results since 2018. CaRi-Heart The technology’s ability to help predict heart attacks has been published in leading medical journals such as Lancet, JACC, European Heart Journal, and Cardiovascular Research. In a new study recently presented at the American Heart Association’s Current Scientific Sessions, CaRi-Heart This technology can predict fatal and non-fatal cardiac events independently of routine clinical risk scores and standard CCTA interpretation, transforming risk stratification and management of patients undergoing routine CCTA. This may have a significant impact on the treatment of CAD.

Find Kalisto online at our website and on LinkedIn. X.

About heart and lung health

Heart & Lung Health (HLH) is a UK-based group of cardiothoracic radiology subspecialists providing radiology reports to NHS trusts, private practices and academia. We also provide expert advice to large corporate organizations. HLH uses innovative technology to deliver fast, reliable, proprietary subspecialty imaging reports focused on providing world-class patient care. HLH Radiologists offer subspecialty cardiothoracic expertise tailored to individual lung and heart conditions, thereby providing a bespoke, personalized diagnostic report for every cardiothoracic image. HLH partners with leading post-processing software and artificial intelligence companies and has a robust audit system to ensure high-quality performance and industry-leading delivery times. HLH can provide cardiac reports for “backlog” clearance, ad hoc research, or as an “end-to-end” service with the scan acquisition company. For more information, please email us at info@heartlunghealth.com.

Callisto Diagnostics Contact Information:
Frank Chen, CEO of Caristo Diagnostics
Frank.cheng@caristo.com

Logo – https://mma.prnewswire.com/media/2054669/4597788/Caristo_Logo.jpg
Logo – https://mma.prnewswire.com/media/2364235/Heart_Lung_Health_Logo.jpg

View original content to download multimedia: https://www.prnewswire.com/news-releases/heart–lung-health-selects-caristo-diagnostics-ai-technology-to-provide -early-diagnosis-of-coronary-arterial disease-UK-wide-302090901.html

Source Callisto diagnosis